Showing results (691-700 of 706) with videos related to

Sort By:
Pageof 71
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Geophysical Research Letters|December 22, 2017
BedMachine v3: Complete Bed Topography and Ocean Bathymetry Mapping of Greenland From Multibeam Echo Sounding Combined With Mass ConservationM Morlighem, C N Williams, E Rignot, et al.
Breast (Edinburgh, Scotland)|July 25, 2026
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastasesThomas Grinda, Hillary M Heiling, Nabihah Tayob, et al.
Breast Cancer Research and Treatment|August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypesLauren Lenz, Chris Neff, Cara Solimeno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
JCO Oncology Advances|May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 TrialMoriah Forster, Fengmin Zhao, Sarah Bell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)E L Mayer, D Hlauschek, M Gnant, et al.
Science Translational Medicine|August 11, 2017
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistanceJennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Breast Cancer Research and Treatment|March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Pageof 71